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Macular telangiectasia type 2 (Mac Tel 2) also known as idiopathic perifoveal telangiectasia and juxta-
foveolar retinal telangiectasis type 2A is an enigmatic disease of unknown etiology. It manifests both
neurodegenerative and vasculopathic characteristics.
It manifests itself during the ﬁfth or sixth decades of life. Clinical characteristics include minimally
dilated parafoveal capillaries with loss of the retinal transparency in the area involved, absence of lipid
exudation, right-angled retinal venules, superﬁcial retinal refractile deposits, hyperplasia of the retinal
pigment epithelium (RPE), foveal atrophy and subretinal neovascularization (SRNV). Optical coherence
tomography (OCT) images typically demonstrate outer retinal abnormalities and the presence of intra-
retinal hyporeﬂective spaces that are usually not related with retinal thickening or ﬂuorescein leakage.
The typical ﬂuorescein angiographic ﬁnding is a deep intraretinal hyperﬂuorescent staining in the
temporal parafoveal area. With time this ﬂuorescein hyperﬂuorescence involves the whole parafoveal
area but does not extend to the center of the fovea. Long-term prognosis for central vision is poor,
because of the development of SRNV or macular atrophy. Its pathogenesis remains unclear but multi-
modality imaging with ﬂuorescein angiography, spectral domain OCT, adaptive optics, confocal blue
reﬂectance, short wave fundus autoﬂuorescence, OCT angiography, and clinicopathological correlations
implicate Müller cells. Currently there is no known treatment for this condition.
Copyright © 2015, The Ophthalmologic Society of Taiwan. Published by Elsevier Taiwan LLC. All rights
reserved.1. Introduction
Retinal telangiectasis, characterized by capillary ectasia and
incompetence, may occur secondary to branch retinal vein oc-
clusion, diabetic retinopathy, X-ray irradiation, and carotid artery
obstruction among several conditions.1 In 1982, Gass and Oya-
kawa2 described 27 patients with juxtafoveolar telangiectasis
with no apparent speciﬁc cause. They named this condition
idiopathic juxtafoveolar retinal telangiectasis (IJRT) and classiﬁed
it into four groups. Group 1 represented a localized form of Coats
disease that occurred predominantly in male patients. These eyes
were characterized by unilateral parafoveal retinal telangiectasisfees from Bayer Health and
thalmology Spring Meeting,
treo y Retina de Costa Rica,
ciety of Taiwan. Published by Elsevassociated with lipid and serous retinal exudation that was
thought to be developmental in origin.2 Men with bilateral sym-
metric juxtafoveolar telangiectasis affecting the temporal half of
the juxtafoveolar areas with minimal intraretinal exudation
typiﬁed Group 2 eyes. Group 3 eyes comprised both female and
male patients who had bilateral parafoveolar telangiectasis with
minimal intraretinal exudation. Group 4 eyes included individuals
with familial perifoveolar retinal capillary occlusion and optic disc
pallor.2 By 1993, Gass and Blodi3 identiﬁed 140 patients with this
condition and reassessed their classiﬁcation of IJRT. IJRT was
divided into three groups and each group was further subdivided
into two subgroups. Eyes in Group 1Amost likely represent a form
fruste of Coats disease characterized by congenital telangiectasia
with lipidic serous exudation that affects mostly male patients in a
unilateral pattern. Laser or pharmacologic treatment appears to
be effective in preserving or improving vision in these pa-
tients.2,4,5 Eyes in Group 1B share the same clinical characteristics
as eyes in Group 1A except for the very limited scope of telangi-
ectatic involvement. Group 2A is the most common form of IJRT.
These eyes lack lipid exudation and most of the clinical ﬁndingsier Taiwan LLC. All rights reserved.
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IJRT. This subgroup comprised only two brothers with subtle
retinal juxtafoveolar telangiectasis and bilateral subretinal neo-
vascularization (SRNV). Group 3 eyes were characterized by
bilateral minimal exudation and extensive occlusion of the jux-
tafoveolar capillaries. Patients with Group 3A eyes had only
ophthalmic manifestations, whereas patients in Group 3B also
suffered from a central nervous system vasculopathy.3
Yannuzzi and co-workers6 proposed the most recent and
simpliﬁed classiﬁcation of IJRT. They merged Gass Groups 1A and
1B into a single aneurysmal telangiectasis group which they called
aneurysmal telangiectasia or idiopathic macular telangiectasia type
1 (Mac Tel 1). Gass and Blodi3 Group 2A was renamed as idiopathic
perifoveal telangiectasis, also known as idiopathic macular telan-
giectasia type 2 (Mac Tel 2). Mac Tel 2 was further subdivided into a
nonproliferative stage characterized by telangiectasia and foveal
atrophy; and a proliferative stage characterized by the presence of
SRNV.7 Gass and Blodi3 Groups 2B and 3 were discarded because of
their rarity. In the accompanying editorial, Chew et al7 endorsed
this new classiﬁcation and encouraged its use. For the purposes of
this review, we will refer to IJRT Type 2A as synonymous of idio-
pathic perifoveal telangiectasis or idiopathic Mac Tel 2.
2. Clinical ﬁndings
Most patients complain of nonspeciﬁc symptoms such as mild
blurring of vision, positive scotoma, difﬁculty in reading, and
metamorphopsia.8e11 Initially the visual acuities are relatively
good, in the order of  20/30.12,13 Gass and Blodi3 have described
the biomicroscopic ﬁndings in detail. The earliest ophthalmoscopic
abnormalities seen in this disease are rather subtle and may be
missed easily. Mild grayish discoloration of the retina with loss of
retinal transparency temporal to the fovea is one of the earliest
clinical abnormalities seen in Mac Tel 2. With disease progression,
this loss of retinal transparency surrounds the perifoveal retina in
an oval conﬁguration3,6,14 (Fig. 1). This parafoveal graying becomes
less intense and more difﬁcult to visualize with continuous light
exposure. Following dark adaptation of at least 15 minutes the
parafoveal graying reappears.15 At this stage, the juxtafoveolar
capillary abnormalities will be absent or barely evident. FluoresceinFig. 1. Grayish discoloration of the retina with loss of retinal transparency.angiography (FA) is often required to demonstrate them.6,12,14 With
time, slightly dilated and blunted retinal venules that extend at
right angles into the temporal parafoveolar retina appear. Telangi-
ectatic vessels typically are not associated with lipid exudation or
hemorrhages.3,13 Multiple, golden, tiny, crystalline, refractile de-
posits near the inner retinal surface are a common ﬁnding occur-
ring in up to 45% of eyes2,3,14,16 (Fig. 2). The number of these
deposits may vary from one to more than twenty. Up to 5% of eyes
with Mac Tel 2 will exhibit yellow foveal lesions. These round
intraretinal yellow spots measure anywhere between 100 mm and
300 mm in diameter and cause a minimal loss of the foveolar
depression. They may be confused with Best disease or an adult
form of vitelliform foveomacular dystrophy.3,17e19 Focal atrophy of
the foveolar retina may develop and lead to a lamellar or even a full
thickness macular hole (FTMH).2,3,6,20e27 These areas of foveolar
atrophy have a distinct circular margin with central retinal thin-
ning. They do not extend beyond the edges of the capillary free
zone.22 The surgical management of eyes with FTMH associated
withMac Tel 2 remains controversial. The ﬁndings on OCTmight be
of prognostic value. If the OCT demonstrates irregular moth eaten
edges and there is no evidence of vitreomacular traction, the sur-
gical results will probably be poor.23,25,28 If instead the OCT shows
round, edematous edges typical of an idiopathic macular hole then
the surgical outcome will be more favorable.26
Stellate foci of intraretinal pigmented black plaques composed
of hyperplastic retinal pigment epithelium (RPE) cells may develop
along the right angled vessels inmore advanced cases (Fig. 3). SRNV
may develop in the vicinity of these plaques. Once present, SRNV is
characterized by a rapid loss of vision, retinochoroidal anastomosis,
cystoid macular edema (CME), subretinal hemorrhage, lipid hard
exudates, and disciform scarring.6,18 SRNV in Mac Tel 2 may be
confused with choroidal neovascularization in age-related macular
degeneration (AMD). There are certain features that may help
distinguish between both conditions. SRNV in Mac Tel 2 is not
usually accompanied by a pigment epithelial detachment.6 The size
of SRNV on Mac Tel 2 is also smaller in comparison to AMD.3
3. Multimodality imaging ﬁndings
Because the clinical changes in Mac Tel 2 are rather subtle by
biomicroscopy, particularly in the earlier stages, ancillary imaging
studies are of paramount importance in the diagnosis of this
condition.14,29Fig. 2. Multiple, golden, tiny, crystalline, refractile deposits near the inner retinal
surface.
Fig. 3. Intraretinal pigmented black plaque composed of hyperplastic retinal pigment
epithelium cells.
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dye in the parafoveal temporal areas. Initially, the early phases of
the angiogram show no evidence or barely minimal capillary
dilatation. There is mild staining of the temporal outer parafoveal
retina in the late phases, which spares the foveal center. As the
disease progresses, the telangiectasia extends beyond the temporal
parafoveal area and is manifested as a late oval shaped parafoveal
hyperﬂuorescence3 (Fig. 4). The ﬂuorescein leakage is not related to
cystic spaces.6 There is a signiﬁcant reduction in the size of the
foveal avascular zone (FAZ) in eyes with Mac Tel 2 in comparison
with normal eyes. There have even been two reported cases where
the capillaries invaded the fovea and obliterated the FAZ.30,31 SRNV
appears to originate from the deep retinal circulation and is char-
acterized by early and late ﬂuorescein leakage.6,32
OCT has revolutionized our understanding of Mac Tel 2 by
demonstrating that there is no correlation between retinalFig. 4. Late ﬂuorescein angiogram frame showing oval shaped parafoveal
hyperﬂuorescence.thickening and ﬂuorescein leakage21,33,34 (Fig. 5). Furthermore
intraretinal hyporeﬂective spaces, that have been named as internal
limiting membrane drape, cyst, cystoid, or pseudocystoid spaces by
different authors, are commonly seen but are usually not related to
retinal thickening or ﬂuorescein angiographic leakage21,34e41
(Fig. 6). Interestingly, foveal thickness is decreased in most pa-
tients with Mac Tel 2.11,33e37,42 Spectral domain OCT has also
documented the presence of outer retina abnormalities1 (Fig. 5).
Research prototypes that integrate adaptive optics (AO) with
high-resolution spectral domain OCT provide high resolution
photoreceptor imaging.43e45 AO imaging has shown that eyes with
Mac Tel 2 eyes exhibit a lower cone density and disruption of the
normal cone mosaic pattern. These abnormalities are even present
in areas where the retinal vasculature appears normal.46
One of the earliest changes reported in Mac Tel 2 is an increased
short wavelength fundus autoﬂuorescence (SW-FAF) signal in the
foveal region47 (Fig. 7). As the disease advances the SW-FAF actually
decreases, not only in the central foveal area but also in the par-
afoveal areas, paralleling the increasing RPE atrophy.48
Confocal reﬂectance imaging refers to an imaging modality that
images the fundus after illuminating it with either a confocal blue
light of 488 nm or an infrared light of 820 nm emitted by a scanning
laser ophthalmoscope (SLO).27 Confocal blue reﬂectance (CBR)
imaging demonstrated increased reﬂectance in the majority of
patients with ﬂuorescein angiographic evidence for Mac Tel
2.27,40,49 The increased CBR appeared in an oval parafoveal pattern
that was slightly larger than the area of late phase ﬂuorescein
angiographic hyperﬂuorescence (Fig. 8).
OCT angiography demonstrates that the earliest vascular
changes in Mac Tel 2 arise in the outer deep capillary plexus.50,51 As
the disease progresses, the vascular changes also involve the inner
superﬁcial plexus, albeit to a lesser extent than the changes seen in
the outer plexus.51 The vessels appear less densely packed, thinner,
and in an abnormal arrangement. The normally avascular Henle
layer and the outer nuclear layers become the target of a vascular
invasion. Anastomosis between plexi and dragging of vessels
temporally are also seen by OCT angiography.50
4. Functional testing
Mac Tel 2 has been studied extensively with microperimetry.1
Microperimetric ﬁndings show that eyes with Mac Tel 2 despite
having a relatively good visual acuity, exhibit severe localized
dysfunction next to ﬁxation early in the disease process. Fortu-
nately these scotomata do not appear to progress rapidly. A longi-
tudinal study showed that after 1 year of follow-up, MP1 testing
with a 20 central testing grid did not show any differences beyond
the normal testeretest variability.52
5. Pathophysiology
The pathogenesis of Mac Tel 2 remains an enigma. Reports of
familial and monozygotic twin cases suggest a genetic component
despite the absence of established hereditary patterns.3,53e57
Multimodality imaging coupled with clinicopathological studies
and the recent discovery of animal models have implicated Müller
cells in the disease process.58e60
Because Müller cells span the entire retinal thickness, some
have suggested that they function as optical ﬁbers that permit
light transmission with a minimum of reﬂection across the retina.
Any pathological involvement of Müller cells would interrupt this
mechanism causing limited transmission and an increase in
retinal reﬂectance.61 The loss of retinal transparency and acqui-
sition of the grayish discoloration seen clinically may be explained
by Müller cell impairment. Jindal et al15 have hypothesized that a
Fig. 5. Optical coherence tomography demonstrating no correlation between retinal thickening and ﬂuorescein leakage. Notice the disruption of the outer retina as well.
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from the impaired Müller cells is responsible for the changes in
intensity in parafoveal graying seen with increasing light expo-
sure and dark adaptation.
The superﬁcial retinal crystalline deposits are thought to be the
footplates of degenerated Müller cells and analogous to Rosenthal
ﬁbers. Rosenthal ﬁbers are crystalline intracytoplasmic inclusions
found in astrocytes of the central nervous system associated to
chronic stress conditions.18,21
Even though the ﬂuorescein angiographic ﬁndings are similar to
the ones found in retinovascular diseases such as DME, there are
subtle differences that were recognized by Gass.62 In Mac Tel 2,
retinal ﬂuorescein staining occurs prior to capillary dilation. Gass62
speculated that this ﬁnding was caused by staining of the extra-
cellular matrix and intracellular diffusion of the dye into the
damaged retinal cells rather than to a breakdown of the blood
retinal barrier leading to an increased retinal vascular perme-
ability.62 He then suggested that the primary abnormality of Mac
Tel 2 resided in the parafoveal neural cells or in Müller cells rather
than the deep outer retinal juxtafoveolar capillaries. He concluded
that the retinal vascular abnormalities were a secondary rather
than the primary phenomenon.62 AO imaging clearly demonstrates
that neural degeneration precedes retinal vascular involvement,
lending support to Gass's hypothesis.46
OCT further differentiates Mac Tel 2 from other retinovascular
diseases by documenting the presence of intraretinal hypore-
ﬂective spaces that do not correlate with an increased retinal
thickness or ﬂuorescein leakage.1,29 These hyporeﬂective spaces
most likely do not represent ﬂuid-ﬁlled spaces as seen in CME
secondary to retinal vein occlusions or diabetic macular edema
(DME). The density of these hyporeﬂective spaces can be measured
and compared to the vitreous density by analyzing the light
reﬂectivity proﬁles from OCT. In eyes with neurodegenerative
conditions such as cone dystrophy, there is less light reﬂectivity as
compared to eyes with exudative conditions such as DME or central
serous chorioretinopathy.63 Müller cells play an important role in
the structural integrity of the fovea.64 The OCT ﬁndings suggest that
these hyporeﬂective spaces may represent cavity formation after
photoreceptor and/or Müller cell loss rather than ﬂuid accumula-
tion caused by blood retinal barrier breakdown associated with
exudation or inﬂammation.63
SW-FAF imaging of the normal macula is characterized by a
central dark area. Absorption of the blue light by the luteal macular
pigments and the RPE melanin are responsible for this ﬁnding.65 In
Mac Tel 2, an increase of SW-FAF in the foveal region precedesclinical and ﬂuorescein angiographic ﬁndings.47 Because histo-
pathological ﬁndings show that the RPE is healthy in Mac Tel 2, the
increased SW-FAF is most likely the result of macular pigment
depletion from the fovea rather than an increased lipofuscin
accumulation in the RPE.66,67 The increased CBR may also be
explained by a decrease in macular pigment in the parafoveal area.
Because the absorption maximum of macular pigment is in the
range of blue light at approximately 460 nm, a decrease in macular
pigment in the parafoveal area will cause an increased reﬂection or
a decreased absorption of the blue light.27,68 Heterochromatic
ﬂicker reﬂectometry and subtraction autoﬂuorescent imaging at
488 nm and 514 nm conﬁrm the loss of macular pigment optical
density (MPOD) in these eyes.47,69,70 Disease severity as docu-
mented by late FA leakagemirrors changes in the distribution of the
MPOD.70
The human body cannot produce macular pigment; therefore,
the macular pigment is entirely of dietary origin. Our bodies can
convert lutein into zeaxanthin but not zeaxanthin into lutein.71
Upon ingestion, high-density lipoprotein transports both zeax-
anthin and lutein into the bloodstream.72 The speciﬁc molecular
mechanisms that mediate the selective uptake, concentration, and
stabilization of the macular pigment are currently unknown.
Macular pigment binding proteins have been immunolocalized to
the cone and rod inner segments.73e75 Quantiﬁcation of macular
pigment has shown a greater reduction in zeaxanthin compared to
lutein in Mac Tel 2 eyes. It is currently unknown if the main
problem is retinal failure to convert lutein into zeaxanthin or
zeaxanthin accumulation.76 These ﬁndings can be attributed to a
primary loss of macular pigment secondary to defective transport
or storage of macular pigment or a progressive pathological process
that damages the anatomic structures that affect macular pigment
accumulation.69,70,76 Oral supplementation with 12 mg of lutein
and 0.6 mg of zeaxanthin daily for 9 months increased macular
pigment in areas where the macular pigment was present at
baseline, but did not produce an increase in macular pigment in
areas where the macular pigment was previously absent.69
Clinicopathological correlations of eyes with Mac Tel 2 conﬁrm
these ﬁndings of depleted macular pigment.58,59 Luteal pigment
was characteristically absent in these eyes. Immunohistochemical
analysis demonstrated the loss of perifoveal Müller cells. Interest-
ingly there was a topographical correlation between areas of
macular pigment absence and areas of Müller cell depletion.58
Müller cells may serve as a retinal reservoir for macular pigment
but the exact details of how Müller cells affect trafﬁcking, deposi-
tion, and storage of the macular pigment are currently unknown.64
Fig. 6. Optical coherence tomography demonstrating intraretinal hyporeﬂective spaces not related to retinal thickening.
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retinal neurons and also play a role in inducing andmaintaining the
integrity of the blood-retinal barrier. Their processes are intimately
related to the retinal blood vessels in the deep outer plexus. By
contrast, the retinal blood vessels in the superﬁcial inner plexus are
closely related with retinal astrocytes.58,77e79 OCT angiography
demonstrates prominent vascular abnormalities in the outer deep
capillary plexus. Vascular invasion of normally avascular retinal
areas such as the subretinal space or the outer nuclear layer may
represent a compensatory mechanism for the ischemic insult
caused by the vascular abnormalities.
Recently a transgenic mouse model with conditional ablation of
Müller cells has been described.60 These animals exhibit photore-
ceptor apoptosis, retinal telangiectasis, breakdown of the blood
retinal barrier and intraretinal neovascularization. It is hoped that
with this model further advancements in our understanding of Mac
Tel 2 can be made.6. Treatment
The main limitation in the treatment of Mac Tel 2 is the lack of
knowledge of the basic pathophysiologic mechanisms underlying
this condition. FA was the earliest imaging modality used to study
this disease. Because the typical angiographic ﬁndings suggested
the presence of macular edema, it was thought that Mac Tel 2 was a
primary retinovascular disease. Therefore, the same treatment
modalities used to treat retinovascular diseases, such as macular
laser photocoagulation,80 intravitreal triamcinolone,81 photody-
namic therapy,82 and intravitreal anti-vascular endothelial growth
factor (anti-VEGF) agents,83 were used to treat Mac Tel 2. None of
thesewere particularly beneﬁcial in eyes with nonproliferative Mac
Tel 2.1 In some eyes with Mac Tel 2, SRNV will develop. These eyes
may beneﬁt from anti-VEGF treatment.1
Several animal models of retinal degenerative diseases have
shown that multiple cytokines, neurotrophins, and growth factors
Fig. 8. Confocal blue reﬂectance imaging showing increased reﬂectance.
Fig. 7. Short wavelength fundus autoﬂuorescence (SW-FAF) imaging of the normal
macula is characterized by a central dark area. In Mac Tel 2 there is an increased SW-
FAF signal in the foveal region.
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receptors.84e86 Based on the premise that Mac Tel 2 has a neuro-
degenerative component, neuroprotective agents such as CNTF are
currently undergoing testing. Delivery of CNTF via encapsulated
cell technology (ECT) into the vitreous cavity has overcome a major
challenge in retinal CNTF delivery. In ECT, genetically engineered
live cells are placed within a semipermeable polymer capsule that
is implanted surgically at the pars plana. These cells secrete the
therapeutic protein of interest in a continuous fashion directly into
the vitreous cavity.87 ECT containing CNTF appears to be safe and
well tolerated in eyes withMac Tel 2 as evidenced by the results of a
recently concluded phase 1 trial.88In summary, Mac Tel 2 is an enigmatic condition characterized
by dual neurodegenerative and vasculopathic pathways secondary
to Müller cell dysfunction. The exact cause of this dysfunction re-
mains unclear. Currently there is no treatment available to halt or
alter the progression of this disease. Although anti-VEGF treatment
seems to limit SRNV in the ﬁnal proliferative stage of the disease,
previous stages currently are not treatable.1References
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